Skip to content

Clinical research with cannabinoids low doses to treat Alzheimer's disease

Clinical investigation with Cannabinoid microdoses for the treatment of Alzheimer's disease

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
REBEC
Registry ID
RBR-4cs7kjz
Enrollment
Unknown
Registered
2021-05-07
Start date
2020-10-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease

Interventions

The study proposes to evaluate the microdosing effect of a Cannabis sativa extract rich in THC in patients with Alzheimer's Disease. The aim of the study is to assess the effects on cognitive symptoms

Sponsors

Universidade Federal da Integração Latino-Americana
Lead Sponsor
Associação Brasileira de Apoio a Cannabis Esperança
Collaborator

Eligibility

Age
60 Years to 100 Years

Inclusion criteria

Inclusion criteria: 60 years old or older; to be diagnosed with Alzheimer for at least 1 year

Exclusion criteria

Exclusion criteria: to have diagnostic of other dementias or correlated diseases; família historic of psychosis; ilegal psychoactive drugs use

Design outcomes

Primary

MeasureTime frame
We hope to find a significant improvement in the cognitive and memory parameters of patients, for this we will use the Mini-Examination of mental state and Adas-Cog tests that will be applied to patients and the DSRS cognition and memory test that will be applied to the caregiver. We expect a reduction in the scores of the indicated tests, reaching a degree of an individual without Alzheimer's disease and that during the 12 months that will be evaluated that these parameters remain stable

Secondary

MeasureTime frame
We expect an improvement in sleep quality and excessive daytime sleepiness in individuals with Alzheimer's disease;Improvement in neuropsychiatric symptoms, for this we will use the Neuropsychiatric Inventory, Cornell scale for depression in dementia and geriatric depression scale;Improvement in the quality of life in individuals with Alzheimer's Disease and their respective caregivers, we will use the questionnaire of quality of life in Alzheimer's Disease version patient and caregiver

Countries

Brazil

Contacts

Public ContactFrancisney Nascimento

Universidade Federal da Integração Latino-Americana

francisney.nascimento@unila.edu.br+5545999333479

Outcome results

None listed

Source: REBEC (via WHO ICTRP)